Payer and Health Technology Assessments

Securing access to psychedelic therapies requires working with payers and health technology assessment (HTA) bodies after regulatory approval. These therapies combine drug treatment with psychotherapeutic support, making them different from standard drug-only medicines and creating unique challenges for reimbursement decisions. Understanding how to work with these bodies is key to making treatments available to patients.

HTA occurs at different levels across Europe. While the European Union conducts Joint Clinical Assessments (JCA) focusing on clinical effectiveness, the most influential assessments occur at the national level. These national HTAs, along with some regional ones, examine both clinical and economic aspects of new treatments. Each country has its own process, with different requirements and expectations that developers must understand.

This chapter outlines how to work effectively with payers and HTA bodies. It covers what evidence they need to see, particularly around how well treatments work compared to existing options and whether they provide value for money. The chapter also looks at practical challenges, such as the combined nature of these therapies and whether healthcare systems are ready to deliver them. By understanding these requirements early and planning carefully, developers can improve their chances of securing reimbursement and making treatments available to patients who need them.

Understanding HTA and Payer Evidence Requirements

Clinical Efficacy

Demonstrating Comparative Efficacy

Comparative efficacy evaluation serves as the foundation for reimbursement and pricing decisions. Unlike regulatory approval, which often hinges on placebo-controlled trials, HTAs demand insights into a treatment's performance relative to existing standards of care. The European HTA landscape, guided by Regulation (EU) 2021/2282, emphasises this through EU-led joint clinical assessments (JCAs) while retaining room for national-level customisation.[16]1

​Direct Comparisons: The Gold Standard

Direct comparison trials are the best way to show how well a new treatment works against existing ones. These trials can compare the benefits and risks of psychedelic therapies with current treatments like antidepressants or talking therapies. No developer has yet started these kinds of trials for psychedelic therapies outside of esketamine (Spravato), even though they are critical.

Running these comparison trials is difficult and expensive, particularly for treatments that include therapy sessions and need special treatment rooms. Despite these challenges, speakers commenting on the HTA evaluation at the EMA 2024 meeting on psychedelics made it clear that these direct comparison trials will be needed to prove how well these new treatments work compared to current options.

Alternative Approaches: Indirect Comparisons

When direct comparison trials are not possible or developers have chosen not to complete such studies, indirect treatment comparisons (ITCs) offer another way to evaluate how well treatments work against each other. This method allows researchers to combine and analyse data from separate clinical trials that share common comparison groups.

Some developers are completing or considering study designs that use neither standard of care nor inert placebo, instead opting for an 'active placebo' compound with dissociative effects. While this approach aims to maintain blinding and demonstrate the clinical effect of the psychedelic arm more clearly, it creates methodological challenges for payer assessment. These challenges extend beyond just the choice of comparator—the presence of psychosocial support across both active and control arms means that even studies with inert placebos may face difficulties in network meta-analyses (NMAs), as the supportive care component differs from trials of standard treatments.

Under the EU's new Joint Clinical Assessment (JCA) procedure, indirect comparisons remain important for demonstrating relative effectiveness when head-to-head trials are unavailable. However, HTA bodies vary widely in how they view ITCs, from Germany's acceptance of ITCs only when sufficient comparability is given (which is rare) to NICE's acceptance of ITCs with appropriate consideration of uncertainty.

These indirect comparisons have important limitations. Common challenges include differences between patient groups across studies, variations in how outcomes are measured, and questions about statistical methods. To address these issues, developers should emphasise the importance of clearly documenting assumptions and conducting sensitivity analyses to test how robust the findings are (van Beekhuizen et al., 2024). NICE's guidelines note that indirect comparisons are particularly vulnerable to systematic bias in networks with few trials, and researchers should consider population adjustment methods when there are imbalances between trials (NICE, 2023).

Researchers should follow established guidelines for choosing appropriate comparison treatments and statistical approaches to make indirect comparisons more credible. NMAs and matching-adjusted indirect comparisons (MAICs) represent commonly used methods, but their success depends on careful attention to methodology and transparent reporting. While the JCA focuses on clinical effectiveness at the EU level, national HTA bodies may have additional requirements for economic evaluations and local decision-making.

Navigating the European Landscape

The JCA process aims to streamline HTA assessments across the EU, while Member States retain autonomy for local decision-making. As the impact of JCAs evolves, developers should plan for EU-level and national requirements. For psychedelic therapies specifically, unique challenges exist around blinding, expectancy effects, and integrating psychotherapeutic components, requiring innovative trial designs and early dialogue with HTA bodies.

Subgroup Analyses

Subgroup analyses help determine how treatments may work differently in distinct patient populations within an approved indication. They are particularly important when a treatment's additional benefit is unclear, when many patients could receive treatment, or when the budget impact is substantial—situations where payers might consider reimbursing treatment for only specific patient groups.

Importance to HTA and Payers

HTA bodies and payers use subgroup analyses to refine their value assessments. NICE (2013; 2023) emphasises the need for subgroup-specific estimates of clinical and cost-effectiveness, particularly when there are biological or clinical reasons to expect different treatment effects. These estimates help target reimbursement to patients most likely to benefit. Different countries handle subgroups differently. For instance, while some might limit reimbursement to specific subgroups, Germany evaluates clinical benefits across all indicated patients, with subgroup results affecting overall pricing discussions.[17]2

Methodological Challenges

Good subgroup analyses need careful planning and explicit methods. Groups should be defined before the analysis begins, with clear reasoning based on biological or clinical factors (EC, 2024). While exploratory analyses can generate new ideas, investigators must interpret them carefully to avoid overestimating effects. Statistical tests for interaction can help prove that subgroup differences are real, especially when results are consistent across multiple studies.

Key challenges include maintaining statistical accuracy with smaller patient numbers and managing multiple comparisons. Small subgroups can lead to unreliable results or bias. Testing many subgroups or outcomes requires statistical adjustments to maintain reliable conclusions, using established statistical methods or more advanced modelling approaches.

Practical Considerations for Psychedelics

Subgroup analyses are particularly relevant for psychedelic therapies, given how responses can vary based on demographic, genetic, and psychological factors. For example, comparing outcomes between treatment-resistant depression (TRD) and first-line cases could show different effectiveness levels, helping to build specific value cases for different populations. These analyses can also help elucidate the role of various treatment components, such as the intensity of subjective effects or the strength of therapeutic alliance, in driving outcomes.

By incorporating well-designed subgroup analyses into their evidence generation, developers can better meet HTA and payer expectations, supporting fair and cost-effective access to innovative treatments across diverse patient populations.

Cost-Effectiveness

Health Economic Modelling

Health economic models help decision-makers understand whether new treatments provide an effective use of funds where there are limited healthcare resources. These models compare the costs of a treatment with its health benefits, often using a measure called the Incremental Cost-Effectiveness Ratio (ICER). The ICER shows how much extra money is needed to gain one additional year of healthy life (called a Quality-Adjusted Life Year or QALY).

For psychedelic therapies, cost-effectiveness analyses (CEAs) and cost-utility analyses (CUAs) are especially important because they can provide a balanced view on clinical and cost implications over time, including future cost savings, compared to current standard treatments for mental health conditions. While psychedelic therapies involve intensive therapeutic support and medication costs, they may reduce long-term healthcare expenses through fewer hospital stays, reduced relapses, and decreased use of chronic medications. Since psychedelics are new to modern healthcare, these models must carefully consider uncertainties about long-term results and test different scenarios to ensure their conclusions are reliable.

Current Landscape of Psychedelic Cost-Effectiveness Evaluations

Economic modelling for psychedelics is still in its early stages in Europe, with only a few studies providing initial frameworks and evaluating cost-effectiveness compared to a handful of standards of care (various psychological interventions). These studies highlight key challenges around pricing assumptions and data limitations (McCrone et al., 2023; Buiter, 2023). Early work on psilocybin therapy for depression in the UK has shown promising health gains in terms of QALYs. Still, it suggests that achieving cost-effectiveness will require significant reductions in therapist and drug costs (McCrone et al., 2023).

Similar challenges emerge in other European analyses, such as the evaluation of MDMA therapy for PTSD in the Netherlands, where researchers found that while cost-effectiveness ratios could fall within acceptable ranges, this heavily depends on the choice of comparator treatments and key assumptions about therapy delivery and outcomes (Buiter, 2023).[18]3

Target Population Selection and Cost-Effectiveness Implications

The selection of target patient populations significantly impacts cost-effectiveness assessments. First-line treatment populations and larger patient groups typically have access to inexpensive standard treatments, such as generic SSRIs costing only pence per day. This low cost of existing treatments creates a challenging cost-effectiveness barrier for novel therapies, regardless of their clinical effectiveness. For psychedelic treatments, the additional costs of therapist time and infrastructure make demonstrating cost-effectiveness in these populations particularly difficult.

Later-line treatments generally have more favourable conditions for cost-effectiveness analyses. These settings often involve higher-cost branded drug comparators, while treatment-resistant populations may already incur substantial healthcare costs or lack effective standard care options. Despite their intensive delivery requirements, these factors can improve the likelihood of demonstrating cost-effectiveness for psychedelic interventions.

Key Components of Health Economic Models

1. Costs and Resource Use: Economic models must include all relevant costs, including direct drug acquisition costs, therapy sessions, monitoring, and managing side effects. Economic models almost always include direct medical resource utilisation costs (such as clinical staff and facilities). Indirect costs (such as lost work time and caregiver support) appear in only a small proportion of health economic assessments that make decisions on drug reimbursement.

1. Clinical and Humanistic Outcomes: Models calculate health outcomes in natural units (e.g., life years, quality of life) and QALYs, integrating clinical trial data, epidemiological estimates, and long-term projections. Researchers capture the humanistic burden through healthcare utilities, which patients generate through patient-reported outcomes to assess the treatment's impact on their quality of life. These measures can be general (EQ-5D or SF-36) or disease-specific. Analysts often model therapies using decision trees and Markov models to estimate how the disease and treatment effects progress over time.

1. Time Horizons and Discounting: Since psychedelic treatments may have long-lasting benefits, existing models typically look 5-10 years ahead to capture effects like fewer relapses or better quality of life. The need to capture these long-term effects requires analysts to extrapolate benefits and validate them with clinical data, expert opinion, or precedence from existing models or expert groups. Analysts adjust future cost savings and clinical benefits downward (by 3-5% per year) to reflect that benefits now are worth more than benefits later.

1. Sensitivity Analyses: Models test different scenarios because many factors are uncertain (such as total treatment costs and how well treatments work over time). These sensitivity analyses help decision-makers understand how cost-effectiveness varies under different assumptions and the probability of staying within any pre-specified cost-effectiveness thresholds.

Country-Specific Variations in Economic Evaluations

While EU Regulation 2021/2282 aims to harmonise HTAs in evaluating clinical effectiveness at the EU level, significantly different approaches to economic analysis have developed in individual countries over time and will persist in the future:

• Germany (IQWiG/G-BA): Health economics plays no role in the national benefit assessment but can be useful in access discussions with individual health insurance companies.

• Netherlands (ZiN): Makes use of cost-effectiveness analysis to inform reimbursement decisionsand can also adopt a societal perspective if these are significant, such as valuing productivity gains and caregiving reductions. Uses flexible thresholds (€20,000 to €80,000 per QALY) linked to disease severity, making it more receptive to therapies with broader benefits.

• United Kingdom (NICE): NICE sets clear cost-effectiveness thresholds of £20,000–£30,000 per QALY, primarily focusing on direct healthcare system costs and cost savings. However, NICE can accept higher thresholds in certain cases of higher unmet needs. While supplementary analyses may consider societal benefits, they rarely influence the primary assessment and final reimbursement recommendation.

• Czech Republic (SÚKL): Employs a healthcare system perspective that focussed primarily on direct medical costs and resource utilisation. The assessment framework emphasises budget impact and affordability considerations, in addition to cost-effectiveness analysis.

These differences in both HTA methodology and health economic thresholds mean psychedelic therapies may be assessed more favourably in some markets than others, particularly where indirect benefits are valued and higher cost-effectiveness thresholds apply.

Balancing Upfront Costs with Long-Term Savings

Healthcare payers often hesitate when treatments need significant upfront investments, which is particularly true for psychedelic therapies that combine drugs with therapy support. While these treatments hold potential for lasting benefits—like fewer relapses and less need for ongoing medications—proving these long-term savings is difficult without extended patient data.

When making economic cases for psychedelic treatments, it will be important to consider both sides: the initial costs (treatment delivery, facilities, and therapist training) and potential future savings (fewer hospital stays, lower medication costs, and patients returning to work). To help address concerns about high initial costs, flexible payment arrangements could be considered, such as payment by results or phasing in coverage gradually, especially where treatment-resistant patients exist in significant numbers.[19]4

Inclusion of Indirect Costs and Benefits

Indirect costs capture health interventions' broader economic and societal impacts beyond direct medical expenses. These costs include productivity losses due to temporary absence from work, reduced working capacity caused by illness or disability, and early death. For psychedelic therapies, which aim to improve mental health conditions such as depression and PTSD, indirect cost savings could be substantial if treatments enable patients to return to work, maintain employment, or reduce reliance on caregivers.

Health economists use two main approaches to calculate indirect costs (Mennini & Gitto, 2022):

• Human Capital Method: Estimates lost productivity based on the time individuals cannot work, valuing their absence at average wage rates.

• Friction Cost Method: Focuses on the costs of temporarily replacing an employee who can not work, accounting for labour market dynamics and adjustments.

Both approaches offer insights into the economic consequences of untreated mental illness and the potential gains from effective interventions. For psychedelic therapies, which may provide durable benefits after a short treatment period, these frameworks can help illustrate potential long-term value.

National Approaches to Indirect Costs: Divergence Across Europe

European countries differ significantly in their approaches to incorporating indirect costs into health economic evaluations, reflecting broader philosophical and methodological perspectives on healthcare spending (García-Mochoón et al., 2022).

Countries such as England and the Czech Republic primarily adopt a healthcare perspective, focusing on direct medical costs related to treatment and excluding broader economic impacts in base-case analyses. While this perspective simplifies calculations, it may fail to capture the full value of therapies, particularly those with non-traditional delivery models that have the potential to lead to a step-change in outcomes, such as psychedelics.

In contrast, countries including the Netherlands, Sweden, and Denmark may employ a societal perspective, incorporating indirect costs and benefits into primary analyses. For example, the Netherlands explicitly accounts for productivity gains, reduced caregiver burden, and societal contributions, making it more receptive to therapies that promise long-term economic benefits despite high initial costs.

Economists also use hybrid approaches in countries like France and Belgium, where they exclude indirect costs from base-case health economic evaluations but may include them in supplementary analyses. This flexibility allows decision-makers to consider broader impacts without compromising methodological consistency.

Budget Impact

Affordability for Health Systems

Budget impact analyses (BIAs) assess how new treatments affect healthcare spending, typically over 3-5 years. Unlike cost-effectiveness analyses, BIAs focus on practical affordability within existing budgets. They estimate the financial impact on the pharmaceutical drug budget or, potentially, the combined budget impact across the health system related to overall service delivery.

For psychedelic therapies, which have high initial costs but potentially long-term savings, the way analysts conduct BIAs may lead to wildly varying outputs for decision-makers. For example, BIAs that look only at pharmaceutical costs will look very different from those that include infrastructure setup and therapist services. Where decision-makers consider budget impact high, this situation more likely leads to reimbursement restrictions and price negotiations with payers.

European Approaches to Budget Impact

The European and U.S. healthcare systems differ significantly in how they approach affordability and financial planning.[20]5 In Europe, public healthcare systems often focus on cost containment and equitable access, using centralised negotiations to determine coverage and pricing. BIAs in Europe often emphasise system-level affordability and resource allocation, reflecting broader societal goals.

Most European countries will require budget impact analysis of a new drug's expected national direct drug costs over 3-5 years at a minimum. Some budget analyses stipulate the inclusion of all direct costs to the health system. The Netherlands’ ZiN methodology incorporates societal costs into economic models, extending the scope of BIAs beyond direct healthcare spending.

Key Considerations for Psychedelics

Psychedelic treatments present unique budget challenges because their costs are "front-loaded"—concentrated in initial treatment phases rather than spread over time like traditional medications, especially for chronic mental health conditions. Key questions include:

• Patient Population Size: How many patients will receive treatment in the first few years? Will eligibility criteria limit uptake?

• Adoption Rates: How quickly can treatment centres be established, and how will infrastructure constraints impact rollout?

• Cost Comparisons: How do psychedelics compare to conventional treatments (e.g., SSRIs or CBT) in terms of annual costs and resource use? Will payers consider cost comparisons to non-pharmaceutical therapies, which are often more cost-intensive?

• Cost Offsets: What savings can health systems expect from quicker hospital discharges, reduced hospitalisations, less emergency care, or reduced long-term medication use?

Target Population Selection and Budget Impact

When developing psychedelic therapies, companies must choose between targeting broader conditions like depression or PTSD or focusing on smaller groups with treatment-resistant conditions. Companies that start with smaller, high-need populations (like TRD) typically combine lower initial total costs with a higher willingness to pay and thus greater payer acceptance while allowing themselves to build evidence through specialised clinics. However, targeting broader conditions could position psychedelics as earlier treatment options, though this will likely raise concerns about overall costs and scalability.

A phased approach, starting with treatment-resistant conditions before expanding to broader populations, often works best to build payer and clinician confidence. This strategy helps prove the treatment's value while managing costs, allowing time to develop infrastructure and gather real-world evidence. Companies can then use this data to support expansion to broader patient groups while giving healthcare systems time to adapt their budgets and resources.

Engaging with HTA Bodies

HTA bodies evaluate new treatments to ensure they provide good value for healthcare systems. For psychedelic therapies, this evaluation is complex because it must consider both the drug effects and the therapeutic component, including how well these work together and their long-term benefits.

This section examines HTA processes in Germany, the United Kingdom, the Netherlands, and the Czech Republic. Each country has distinct requirements. For instance, Germany focuses on proving any added clinical benefit compared to existing treatments, while the UK emphasises cost-effectiveness thresholds. The Netherlands and Czech Republic pay particular attention to affordability and broader societal benefits. Understanding these differences helps developers plan their evidence generation and effectively engage with HTA bodies to support access to psychedelic therapies.

Understanding HTA Processes in Target Countries

Germany (G-BA and IQWiG)

Germany’s HTA process operates under the AMNOG framework (Arzneimittelmarktneuordnungsgesetz), a structured system designed to evaluate new therapies' added clinical benefit following their approval (Bundesministerium für Gesundheit, 2010). The Federal Joint Committee (G-BA), which sets the requirements for evaluation, and the Institute for Quality and Efficiency in Healthcare (IQWiG), which conducts the scientific assessments to inform these decisions, oversee this process. Together, these bodies form the backbone of Germany’s HTA process. Therapies with orphan drug designation and below a certain annual cost threshold are exempt from the regular benefit assessment procedure as the orphan drug designation is based on a clear unmet need and noted benefit vs. existing medicines.

Initial Submission Process

The AMNOG process begins immediately after a therapy enters the German market. Within three months of market entry, IQWIG begins assessing the manufacturer's dossier detailing the therapy's clinical and economic evidence to the G-BA. This dossier includes data on efficacy, safety, and patient-relevant outcomes and comparative evidence against the appropriate comparator therapy determined by the G-BA.

This step introduces complexities for psychedelic therapies, as the combined drug-and-therapy model necessitates data not only on the pharmacological intervention but also on the accompanying psychotherapy if it is part of the indication. Developers must demonstrate the synergy between the two components, clearly outlining how this integrated approach provides superior clinical outcomes compared to existing treatments.

Early Benefit Assessment

Once the dossier is submitted, the G-BA commissions IQWiG to conduct an early benefit assessment (frühe Nutzenbewertung). This assessment evaluates the therapy’s comparative effectiveness, improvements in patient-relevant outcomes such as mortality, morbidity, quality of life, and safety profiles. IQWiG does not conduct health economic evaluations. However, the IQWiG assessment forms the foundation for G-BA’s later pricing negotiations with the manufacturer.

The early benefit assessment focuses heavily on comparative evidence, requiring head-to-head trials wherever possible. When such data are unavailable, developers may need to rely on ITCs, which are scrutinised for methodological rigour and relevance.

Benefit Classification and Pricing

Following IQWiG’s evaluation, the G-BA reviews the findings and determines whether the therapy offers an added benefit over standard treatments. G-BA categorises the benefits into major, considerable, minor, non-quantifiable, none, or lower benefit, with higher ratings offering more substantial leverage during price negotiations. Of note, therapies with an orphan drug designation (ODD) and under the set annual cost threshold must receive, at a minimum, a non-quantifiable benefit from the G-BA.

For psychedelic therapies, demonstrating major or considerable benefit will be critical. Establishing long-term efficacy and durability of response may help to achieve favourable ratings, as therapies that address TRD or PTSD may face additional scrutiny regarding their sustained impact and safety profiles. Notably, Spravato achieved a considerable benefit rating due to its patient-relevant benefits in TRD.

Price Negotiations and Market Access

The G-BA’s decision also sets the stage for price negotiations between the manufacturer and Germany’s statutory health insurance association (GKV-Spitzenverband). During the first 6 months of market entry, manufacturers can set their own prices, but subsequent pricing depends on the G-BA’s benefit classification. The GKV typically negotiates therapies rated with no added benefit at parity with or even below existing treatments. In contrast, those demonstrating major or considerable benefit have the potential to achieve higher prices than the existing standard of care.

Post-Marketing Requirements

Beyond the initial assessment, the G-BA may impose post-marketing requirements to monitor long-term outcomes and safety. For psychedelic therapies, this could include Phase IV studies, registry data, and real-world evidence collection to address uncertainties about durability, side effects, and integration protocols. IQWiG’s methodological standards emphasise transparency and reproducibility, requiring developers to document assumptions and data sources used in the evaluations. These post-launch obligations reflect broader uncertainties in psychedelic therapy outcomes and highlight the need for ongoing evidence generation to maintain pricing and reimbursement status.

Unique Challenges and System Integration

Despite Germany’s well-defined HTA framework, psychedelic therapies pose unique challenges, especially if implemented as a combined drug-plus therapy model. Current billing systems, such as the Gebührenordnung für Ärzte (GOÄ) and the Einheitlicher Bewertungsmaßstab (EBM), are poorly equipped to capture the costs of intensive psychotherapeutic support sessions that may be required for psychedelic therapies, potentially limiting accessibility and adoption.[21]6 Developers must also navigate budget constraints imposed on outpatient providers, who may hesitate to prescribe high-cost treatments without explicit reimbursement guarantees from insurers.

The adoption of psychedelic therapies in Germany's healthcare system will likely focus on establishing appropriate funding mechanisms, particularly for outpatient settings, and securing reimbursement for therapist time. While there may be some parallels with esketamine integration, the key challenges appear to centre on developing practical payment pathways that account for the unique delivery model of psychedelic therapy, including longer clinic visits for dosing and psychotherapeutic support.

Germany's HTA system sets a high bar for evidence quality and directly links drug pricing to it. While this presents a challenge for psychedelic therapies, it also provides opportunities to demonstrate their potential as paradigm-shifting treatments for psychiatric disorders. Developers must strategically plan their evidence-generation activities, considering the ability to deliver clinical trials with head-to-head comparative data, the costs and complexity of doing so, and the implications of not doing this on drug pricing in Germany, which is usually an early launch market.

United Kingdom (NICE and SMC)

In the United Kingdom, the evaluation and reimbursement of new therapies falls under the jurisdiction of the National Institute for Health and Care Excellence (NICE) in England and Wales, and the Scottish Medicines Consortium (SMC) in Scotland. The NICE process focuses on evidence-based recommendations and ensuring cost-effectiveness for treatments introduced into the National Health Service (NHS) (NICE, 2023).

Unlike many European countries, the UK does not follow the European Medicines Agency (EMA) approval pathway, requiring manufacturers to engage directly with the Medicines and Healthcare products Regulatory Agency (MHRA) for market authorisation before proceeding to NICE evaluations.[22]7

NICE Health Technology Assessment Routes

Therapies seeking NHS adoption generally follow one of three routes: NICE Health Technology Appraisals (HTA), NHS clinical policy development, or the Clinical Priorities Advisory Group (CPAG) process​.

Among these, the NICE HTA is the most comprehensive and widely applicable route, evaluating clinical and cost-effectiveness and providing binding recommendations on NHS funding and access. The CPAG process, often reserved for rare diseases and highly specialised treatments, may offer a potential alternative for therapies if targeted at small, high-need populations but applies to only a small number of interventions per year. NHS clinical policy development is more relevant for interventions outside NICE’s remit, often focusing on service delivery frameworks rather than specific new technologies, although exceptions exist where drug treatment funding has been reviewed.

Topic Selection and Scoping

The NICE process begins with topic selection, initiated by referrals from the Department of Health and Social Care or NHS England. During the scoping phase, NICE defines the key elements of the assessment, including the target population, relevant comparators, and relevant outcomes​. For psychedelic therapies, this step would identify unique delivery requirements, such as psychotherapy integration, which may create additional challenges in defining cost-effectiveness models and comparators.

Technology Appraisal Framework

Psychedelic therapies are likely to undergo NICE’s Single Technology Appraisal (STA) process, which focuses on assessing one drug for a specific indication. The STA model requires manufacturers to submit detailed dossiers containing clinical trial data, health economic models, and budget impact analyses​ (BIAs).

Given the therapy-drug combination inherent in psychedelic treatments, submissions must address both pharmacological efficacy and the therapy’s delivery framework. NICE evaluates these submissions through independent Evidence Review Groups (ERGs), which appraise the evidence base for clinical and cost-effectiveness​.

Appraisal Committees and Consultation

NICE convenes an independent Appraisal Committee to review evidence and hear input from stakeholders. The committee bases decisions on clinical trial data, cost-utility analyses (typically using QALYs), and economic models that address uncertainties through sensitivity analyses.

Particular scrutiny of psychedelic therapies is likely to focus on the duration and resource intensity of treatment protocols, including therapist time and infrastructure needs. NICE’s reliance on cost-effectiveness thresholds—commonly £20,000–£30,000 per QALY—poses a significant hurdle for therapies with high upfront costs, reinforcing the importance of modelling long-term cost offsets​. In 2022, NICE introduced a severity modifier, allowing the approval of treatments for some severe diseases with a higher cost-effectiveness threshold.

The draft guidance, released as an Appraisal Consultation Document (ACD), is subject to public consultation before the final Appraisal Determination (FAD) is published. Positive recommendations obligate NHS adoption within 90 days, while negative appraisals may lead to developer-triggered appeals or requests for further evidence generation​. Therapies 'not recommended' by NICE may struggle to achieve any meaningful access within the NHS.

During the HTA process, manufacturers may refine the requested patient population for reimbursement or amend the position in the care pathway to take account of initial NICE recommendations of UK clinical practice and the likelihood of meeting cost-effectiveness thresholds. Additionally, manufacturers may reduce the therapy's net price to increase the certainty of meeting cost-effectiveness criteria and the likelihood of a positive final HTA recommendation.

Managed Access and Real-World Evidence

To address novel treatments' uncertainties, NICE may consider Managed Access Agreements (MAAs), which conditionally approve therapies while mandating ongoing data collection​. This approach may prove especially useful for psychedelic therapies, where long-term efficacy and economic data will be limited.

The Innovative Medicines Fund (IMF) may provide interim funding for a few therapies while real-world data is collated or longer-term studies are taking place. NICE can later revise recommendations based on this real-world evidence and make a final determination on cost-effectiveness and NHS funding and access.

Regulatory and Implementation Challenges

Despite the rigorous evaluation framework, psychedelic therapies face additional hurdles due to their controlled substance status. Prescribing requirements, storage conditions, and clinical supervision protocols need to be aligned. These factors necessitate collaboration between NICE, the Medicines Value and Access Team (MVAT), and possibly the Home Office, to streamline regulatory and health system implementation.

The Netherlands (ZiN)

In the Netherlands, Zorginstituut Nederland (ZiN) manages HTAs for new therapies, including psychedelics. ZiN determines whether to recommend a treatment for inclusion in the statutory health insurance (SHI) package (basispakket) based on its clinical effectiveness, cost-effectiveness, necessity, and feasibility.

Given the distinct combination of drugs and psychotherapy in psychedelic treatments, the assessment framework must address both pharmacological efficacy and the broader therapeutic context, making this evaluation more complex than for conventional medications.

Regulatory Pathway and Submission Requirements

Following approval by the EMA, manufacturers seeking reimbursement in the Netherlands must submit a dossier to ZiN for evaluation (ZiN, 2024). This dossier must provide comprehensive evidence, including clinical trial data, cost-utility analyses (CUAs), and information on societal impact. ZiN’s assesses the submission using "package management criteria" (pakketbeheercriteria).

These criteria include effectiveness, cost-effectiveness, necessity, and feasibility. Clinical outcomes, such as improvements in symptoms or quality of life, supported by evidence from randomised controlled trials (RCTs) or real-world data, demonstrate effectiveness. ZiN evaluates cost-effectiveness using incremental cost-effectiveness ratios (ICERs) and quality-adjusted life years (QALYs) to determine whether the therapy provides sufficient value for its cost compared to existing treatments. Necessity focuses on whether the therapy addresses a significant unmet medical need. At the same time, feasibility examines whether providers can integrate it practically into the Dutch healthcare system, considering infrastructure requirements and professional training.

The "Lock" (Sluis) Process for High-Cost Therapies

The Netherlands employs an additional review process known as the "lock" (sluis) for therapies with high costs or significant projected budget impacts. This process applies to treatments exceeding €50,000 per patient and €10 million annually in projected costs. It involves more stringent assessments of cost-effectiveness and affordability, often requiring additional data collection post-launch.

Psychedelic treatments will likely avoid this pathway. However, if a therapy enters the lock, it faces further negotiations and may only receive conditional approval, contingent upon collecting long-term evidence to address remaining uncertainties​.

Decision-Making and Reimbursement

ZiN compiles its recommendations into an advisory report for the Minister of Health, Welfare, and Sport, who ultimately decides whether to include the therapy in the basic health insurance package. The advisory report evaluates whether the treatment meets the four key criteria and may propose conditions for reimbursement, such as limiting use to specific patient populations or requiring providers to participate in registries to track long-term outcomes.

For example, psychedelic therapies could be approved only for patients who have not responded to multiple lines of treatment, reflecting a cautious approach similar to that taken with esketamine for TRD. Price negotiations may also follow, particularly for high-cost therapies, with managed entry agreements and risk-sharing arrangements used to balance payer concerns with patient access​.

If the Minister approves the therapy, they list it in the Geneesmiddelenvergoedingssysteem (GVS), which governs reimbursement categories. The Minister may place therapies in Appendix 1A for full reimbursement without restrictions or Appendix 1B for conditional reimbursement, which often includes eligibility criteria or other usage constraints. For psychedelic therapies, the Minister will likely place them in Appendix 1B, particularly in the early stages, as clinicians integrate them into clinical practice and researchers collect additional data.

Cost-Utility Modelling and Indirect Benefits

A key feature of the Dutch HTA process is its emphasis on cost-utility modelling and societal perspectives. The process includes indirect costs and benefits, such as productivity gains and reduced caregiver burden, in its economic evaluations. The Dutch broader perspective aligns well with the potential long-term benefits of psychedelic therapies, particularly for conditions like PTSD and TRD.

However, developers must provide robust data to support these claims, as ZiN applies a sliding scale for willingness-to-pay thresholds based on disease severity and burden. A critical challenge often underestimated by developers is the need to document and substantiate disease severity and burden thoroughly. Historical HTA submissions across various therapeutic areas show that approximately 80% struggle to adequately demonstrate these aspects, potentially limiting their ability to justify higher willingness-to-pay thresholds and secure favourable reimbursement decisions.

Ongoing Monitoring and Real-World Evidence

Conditional approvals often require post-marketing surveillance and ongoing data collection to address uncertainties. Psychedelic therapies may be subject to additional scrutiny, with requirements to participate in registries or conduct Phase IV trials to verify long-term safety and effectiveness. ZiN can also re-evaluate therapies as new evidence emerges, adjusting reimbursement conditions or withdrawing coverage if expectations are unmet.

Challenges for Psychedelic Therapies

While the combination of drug administration and therapeutic support in psychedelic treatments presents a novel evaluation scenario, existing healthcare codes and care pathways may provide useful frameworks for assessing the psychotherapeutic components. The challenge lies primarily in adapting these established structures to this emerging treatment paradigm.

For new treatments like psychedelics, ZiN maintains high standards for evidence quality and cost-effectiveness modelling, including careful evaluation of treatment comparisons. While this presents certain hurdles, the Dutch system's mechanisms for managed entry agreements and conditional approvals provide a structured but adaptable pathway for integrating novel therapies into standard care, particularly when direct comparative evidence may be limited.

Czech Republic (SÚKL)

In the Czech Republic, new therapies undergo a structured HTA process managed by the State Institute for Drug Control (SÚKL). This evaluation focuses on clinical effectiveness, cost-effectiveness, and budgetary impact to determine eligibility for inclusion in the public health insurance system. Most new drugs, particularly innovative therapies like psychedelics, secure centralised marketing authorisation through the EMA. Once the EMA grants approval, it applies across EU Member States, including the Czech Republic, streamlining the initial regulatory phase.

A national authorisation route through SÚKL remains an option for less complex therapies, although developers rarely pursue this route for innovative treatments. Instead, developers of psychedelic therapies are more likely to rely on EMA approval and direct their efforts toward addressing the Czech Republic’s economic and logistical requirements for reimbursement. This approach reduces duplication of scientific evaluations and positions EMA approval as a baseline for local pricing and coverage discussions.

Dossier Submission and HTA Evaluation

Following EMA authorisation, manufacturers submit a detailed dossier to SÚKL to request registration and inclusion in the public health insurance system. The dossier comprises clinical data, economic models, and budget impact analyses tailored to the Czech healthcare landscape. Clinical evidence is typically derived from the EMA’s centralised assessment, minimising the need for re-evaluation. However, pharmacoeconomic models must be customised to demonstrate cost-effectiveness in the Czech context.

SÚKL applies strict requirements for proving therapeutic value and cost-efficiency. Submissions must quantify health gains using incremental cost-effectiveness ratios (ICERs) and quality-adjusted life years (QALYs) metrics. The agency also requires budget impact analyses to estimate the financial consequences of adopting the therapy, accounting for patient numbers, pricing, and resource use. For psychedelic therapies, this means addressing both drug costs and the logistical requirements of therapist-led sessions and specialised treatment environments.

Pricing and Reimbursement Decisions

A key component of the national pricing and reimbursement process is determining the maximum ex-factory price, known as the “maximální cena výrobce.” SÚKL relies on international reference pricing, comparing costs across EU Member States. Typically, prices from a basket of selected countries cannot exceed the average of the three lowest country prices. This external price benchmarking approach helps control drug pricing and drug costs, but would not manage non-drug costs associated with supervised administration and psychotherapy requirements.

Reimbursement decisions classify drugs into different categories, ranging from full coverage to partial reimbursement with restrictions. Expensive or novel therapies are often subject to conditional reimbursement agreements, particularly if long-term effectiveness data are still emerging. For psychedelics, these agreements may limit coverage to specific subgroups, such as patients with TRD, or require prescribing within specialised clinics to ensure safety and protocol adherence.

Budget Impact Analysis and Economic Modeling

Budget impact analyses (BIAs) address the broader financial implications of adding new therapies to the public health system. Payers scrutinise whether the treatment’s costs are sustainable under existing budgets. If projected costs exceed predefined thresholds, manufacturers may be required to negotiate risk-sharing agreements, such as budget caps or outcomes-based pricing models, to control expenditures.

Economic models for psychedelic therapies must account for drug prices and associated costs, such as therapy preparation, monitoring, and post-treatment integration sessions. To offset initial expenses, it is crucial to demonstrate long-term savings through reduced healthcare spending, such as hospitalisations and lower medication use. Conditional reimbursement pathways often include periodic reassessments to verify these projected savings over time.

Implementation and Real-World Monitoring

Once a therapy is approved for reimbursement, SÚKL lists it in the Czech "List of Reimbursed Medicinal Products," which details pricing, reimbursement levels, and prescribing conditions. Physicians and pharmacists must follow these prescribing conditions when prescribing and dispensing, particularly for therapies requiring controlled environments or specialised training, such as psychedelics. SÚKL monitors treatment outcomes through pharmacovigilance programs, ensuring continued safety and efficacy.

Given the novel nature of psychedelic therapies, SÚKL is likely to recommend conditional reimbursement. This designation allows temporary coverage while mandating additional data collection through patient registries or post-marketing studies. This evidence supports future reassessments, enabling SÚKL to refine reimbursement terms or expand coverage based on updated findings.

Therapies that fail to meet expectations during follow-up evaluations may face restrictions or removal from reimbursement lists. Conversely, positive real-world outcomes can justify broader use, reinforcing the importance of robust initial data submissions and ongoing evidence generation for psychedelic therapies.

Special Considerations for Psychedelic Therapies

Psychedelic therapies present unique challenges for HTA evaluations due to their combined drug-and-therapy approach. SÚKL must assess the pharmacological component and the psychotherapy elements, which complicates economic modelling. Evaluators consider the costs of training therapists, maintaining treatment facilities, and ensuring regulatory compliance, which differ significantly from standard pharmaceutical interventions.

Psychedelics also face additional scrutiny under the Czech Republic’s narcotics regulations. Controlled substances require licensing and oversight, adding administrative and legal hurdles to their implementation. Societal attitudes and ethical debates may further influence policymakers, highlighting the need for stakeholder engagement and transparent communication about therapeutic benefits and safeguards.

Preparing HTA Submissions

Preparing submissions for HTA bodies requires combining evidence about a treatment's effectiveness and value. This combination is complex for psychedelic therapies because submissions must cover both the drug effects and therapy components, showing how they work together to help patients.

Submissions must include clinical trial results, comparisons with existing treatments, economic analysis, and budget impacts. Although making these comparisons can be challenging, it is important to show how psychedelics compare to current treatments. Economic analysis must consider all costs—including therapist time, facilities, and follow-up care—while highlighting potential long-term savings and patient life improvements.

Since psychedelic therapies are new, HTA bodies will question their long-term effects. Developers can address these concerns by testing different scenarios in their economic models, suggesting ways to collect more data as clinicians roll out treatments, and being transparent about what researchers know and do not know.

Submissions often benefit from input from doctors, patients, and advocacy groups during the HTA process. Doctors can explain why new treatments are needed, while patients can describe how conditions or specific treatments affect their lives. These perspectives will help demonstrate the broader benefits of psychedelic therapies and increase the chances of approval.

The most effective approach in preparing for HTA submission is to use early advice or early engagement meetings wherever possible. HTA bodies offer these opportunities, ranging from informal discussions with broad-ranging advice to extremely structured processes where reviewers answer specific questions or validate evidence-generation plans. Developers should understand that some advice is binding, while other advice is only guidance, requiring developers to clearly understand the process before initiating engagement.

Innovative Reimbursement Models

Innovative reimbursement models represent a dynamic interface between manufacturers and payers, offering mechanisms to manage uncertainties while enabling access to promising therapies. These models may be particularly relevant for psychedelic treatments, where long-term outcomes and durability of effect remain areas of active investigation. Given the novelty and complexity of these therapies, which combine pharmacological and psychotherapeutic elements, standard pricing and reimbursement approaches may prove limiting, and they could benefit from considering the following approaches.

Outcomes-Based Agreements / Performance Agreements

One potential approach is performance-linked reimbursement, where payers tie payments to predefined patient outcomes. For psychedelic therapies, these outcomes could include sustained remission rates, reductions in hospitalisations, or improvements in quality-of-life metrics. Such agreements reduce financial risk for payers by ensuring that payments reflect real-world effectiveness rather than relying solely on clinical trial data. However, developers must address challenges in defining appropriate metrics and establishing mechanisms for long-term data collection early in the negotiation process.

Managed Entry Agreements

Conditional coverage arrangements, also known as managed entry agreements, allow therapies to enter the market while additional evidence is collected. These models are particularly useful when early clinical data shows promise, but gaps remain regarding long-term efficacy or safety. For psychedelics, this approach could help balance the urgency of treating patients with severe conditions against the need for ongoing evidence generation.

Value-Based Pricing

Another option for psychedelic therapies is flexible pricing strategies based on therapeutic benefits. Value-based pricing aligns costs with demonstrated clinical and economic value, reflecting the therapy’s impact on patient outcomes and healthcare resource utilisation. For psychedelics, this might involve accounting for indirect cost savings, such as productivity gains and reduced caregiver burden, to justify higher upfront costs. However, implementing value-based pricing requires robust health economic modelling and transparent agreements on how value is measured over time, and some payer groups have considered and then abandoned this approach in the past.

A particular challenge for psychedelic therapies in value-based models is the cost structure of delivery. Unlike traditional pharmaceuticals, where manufacturers minimise production costs and maintain pricing flexibility within their margin, psychedelic treatments include substantial fixed costs for therapist time and monitoring that must be paid immediately, regardless of long-term outcomes. The immediate payment requirement for substantial fixed costs creates practical constraints on implementing value-based pricing that are not present with conventional drug-only interventions.

While these models will be explored in greater depth in the "Potential Reimbursement and Access Pathways" chapter, they offer a framework for addressing the uncertainties common in psychedelic therapies. Innovative reimbursement models can bridge gaps between clinical promise and payer requirements by combining evidence development with flexible payment structures, supporting long-term access to these groundbreaking treatments.